Core Viewpoint - On November 6, 39 Hong Kong-listed companies conducted share buybacks, totaling 23.82 million shares and an amount of HKD 160 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 6.81 million shares for HKD 29.43 million, with a highest price of HKD 4.350 and a lowest price of HKD 4.290, accumulating HKD 284.38 million in buybacks for the year [1][2]. - Kintor Pharmaceutical-B bought back 1.73 million shares for HKD 26.31 million, with a highest price of HKD 15.800 and a lowest price of HKD 14.350, totaling HKD 33.98 million in buybacks for the year [1][2]. - COSCO Shipping Holdings repurchased 1.53 million shares for HKD 20.99 million, with a highest price of HKD 13.840 and a lowest price of HKD 13.570, accumulating HKD 46.58 billion in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on November 6 was by China Feihe at HKD 29.43 million, followed by Kintor Pharmaceutical-B at HKD 26.31 million [1][2]. - In terms of share quantity, China Feihe also led with 6.81 million shares repurchased, followed by China Petroleum & Chemical Corporation with 2.40 million shares [1][2]. Group 3: Additional Insights - The buyback by Kintor Pharmaceutical-B was noted as its first for the year [2]. - The total buyback amount for COSCO Shipping Holdings reflects its multiple buyback activities throughout the year [2].

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 6, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 6.806 million shares for a total of 29.4298 million yuan, representing 0.746% of its total share capital [2]. - Kexin Pharmaceutical-B (02171) repurchased 1.734 million shares for 26.3078 million yuan, accounting for 0.380% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 1.53 million shares for 20.9869 million yuan, which is 0.409% of its total share capital [2]. Group 2: Other Notable Buybacks - Gushengtang (02273) repurchased 493,500 shares for 13.7699 million yuan, representing 3.435% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 2.398 million shares for 10.1066 million yuan, which is 0.100% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.38 million shares for 7.4745 million yuan, accounting for 4.298% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include: - Ruisheng Technology (02018) with 165,000 shares repurchased for 6.5033 million yuan [2]. - MGM China (02282) with 400,000 shares repurchased for 6.3701 million yuan [2]. - Huajian Medical (01931) with 922,000 shares repurchased for 5.9985 million yuan [2]. Group 4: Smaller Buybacks - Companies with smaller buyback amounts include: - Yidian Cloud (02416) with 130,000 shares repurchased for 264,000 yuan [3]. - International Home Retail (01373) with 150,000 shares repurchased for 118,500 yuan [3]. - Mobi Development (00947) with 70,000 shares repurchased for 1.167 million yuan [3].

Core Viewpoint - Kintor Pharmaceutical-B has conducted a share buyback on November 6, purchasing 1.734 million shares at a price range of HKD 14.350 to HKD 15.800, totaling HKD 26.3078 million [2] Summary by Category Buyback Details - The company repurchased 1.734 million shares on November 6, with a closing price of HKD 15.680, reflecting a 0.32% increase on that day [2] - The total trading volume for the day was HKD 91.6057 million [2] - Year-to-date, the company has completed three buybacks, totaling 2.189 million shares and an aggregate amount of HKD 33.9758 million [2] Buyback Breakdown | Date | Shares Repurchased (thousand) | Highest Price (HKD) | Lowest Price (HKD) | Total Amount (thousand HKD) | |------------|-------------------------------|---------------------|--------------------|------------------------------| | 2025.11.06 | 173.40 | 15.800 | 14.350 | 2630.78 | | 2025.10.23 | 20.50 | 16.700 | 16.470 | 339.82 | | 2025.10.21 | 25.00 | 17.150 | 16.990 | 426.98 | [2]

Company News - BeiGene reported total revenue of approximately $3.845 billion for the first nine months, a year-on-year increase of 43%. Adjusted net profit was approximately $693 million, marking a return to profitability. In Q3, revenue reached $1.412 billion, up 41% year-on-year, with adjusted net profit of approximately $304 million, a 489% increase year-on-year. The growth is primarily attributed to the sales increase of BeiYueZe® in the US and Europe, with the US remaining the largest market for the company. The full-year revenue guidance is set at $5.1 billion to $5.3 billion, reflecting strong growth expectations from BeiYueZe® in the US and continued expansion in Europe and other key global markets [2] - Yidu International Holdings announced an earnings upgrade, expecting a profit attributable to shareholders of approximately HKD 1.2 billion for the first half, representing an increase year-on-year [3] - Hua Hong Semiconductor reported sales revenue of $635 million for Q3 2025, a year-on-year increase of 20.7%. However, net profit decreased by 42.6% to $25.725 million [4] - Autohome's net profit attributable to the parent company for Q3 was approximately RMB 436.6 million, with online marketing and other business revenues increasing by 32.1% year-on-year [5] - Xinyi International reported a cumulative net operating income of approximately HKD 13.981 billion for the first ten months, a year-on-year decrease of about 5.3%, with October revenue at HKD 1.457 billion [6] - Dongfeng Motor Group's cumulative vehicle sales for the first ten months reached 1.501 million units, a year-on-year decline of approximately 1.6%. However, sales of new energy vehicles increased by approximately 37.1% to 421,400 units [7] - China Overseas Land & Investment reported a cumulative contracted property sales amount of approximately RMB 189.165 billion for the first ten months, a year-on-year decrease of 21.3% [8] - Poly Property Group reported a cumulative contracted sales amount of RMB 43.8 billion for the first ten months, a year-on-year decrease of 10.43% [9] - Gemdale reported a cumulative contracted sales amount of approximately RMB 9.125 billion for the first ten months, a year-on-year decrease of 43.93% [10] - Sunac China reported a cumulative contract sales amount of approximately RMB 32.77 billion for the first ten months, a year-on-year decline of 25.1% [11] - Guoyin Financial Leasing plans to purchase 1,198 units of domestic information technology computing equipment for a total consideration of RMB 1.04 billion [12] - Youjia Innovation recently received project designation notifications from a globally renowned automotive group's joint venture and luxury brand, with a total order amount of approximately RMB 320 million [13] - Swire Properties reported a rental rate of 96% for Taikoo Place in Q3, with a rental reduction of 13%. Other Swire properties had an occupancy rate of 90%, with a rental reduction of 15% [14] - Zhongshen Construction Industry plans to acquire 100% equity of Huajian Development Co., Ltd. for approximately HKD 213.6 million [15] - Hard Egg Innovation signed a memorandum of understanding with Huixin Investment to jointly develop an AIoT innovation enterprise incubation platform [16] - Damai Entertainment expects mid-term net profit to increase to no less than RMB 500 million, compared to RMB 337 million last year [17] - Cafe de Coral Group issued a profit warning, expecting mid-term profit attributable to shareholders to decline by 65% to 70% [18] - Qingci Games signed a game licensing transfer agreement with Disney, obtaining authorization to develop and publish the game "Disney: Book of Legends," expected to launch in 2026 across various regions [19] - Now Medical Technology's subsidiary signed a strategic cooperation framework agreement with Medtronic Changzhou to promote clinical applications of real-time navigation tracking endoscopic technology in China [19] - Zhaoke Ophthalmology-B signed a distribution agreement with PT FERRON for the commercialization of BRIMOCHOL PF in Indonesia, receiving an upfront payment and potential milestone payments [19] - Shoujia Technology signed a strategic framework cooperation agreement with Stardust Intelligence, covering the development of humanoid robot tendon and related fields [20] Buyback Dynamics - Helen's decided to exercise its share buyback authorization, planning to repurchase up to 127 million shares [21] - China Feihe repurchased 6.806 million shares for a total of approximately HKD 29.4298 million, with a buyback price of HKD 4.29 to HKD 4.35 [22] - Kintor Pharmaceutical repurchased 1.734 million shares for a total of approximately HKD 26.3078 million, with a buyback price of HKD 14.35 to HKD 15.8 [23] - COSCO Shipping Holdings repurchased 1.53 million shares for a total of approximately HKD 20.9869 million, with a buyback price of HKD 13.57 to HKD 13.84 [24] - Sinopec repurchased 2.398 million H-shares for a total of approximately HKD 10.1066 million, with a buyback price of HKD 4.20 to HKD 4.23 [25]

Group 1 - Company Kintor Pharmaceutical-B (02171.HK) announced a share buyback on November 6, 2023, spending HKD 26.308 million to repurchase 1.734 million shares [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 1.734 million shares at a total cost of HKD 26.3078 million [1] - The buyback is scheduled for November 6, 2025, reflecting a strategic move to enhance shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 科濟藥業控股有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000,000 | USD | | 0.00000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 200,000,000,000 | USD | | 0.00000025 | USD | | 50,000 | ...

Core Insights - The annual adjustment of the National Medical Insurance (NMI) catalog has progressed, with negotiations for the 2025 NMI drug catalog and commercial insurance innovative drug catalog taking place from October 30 to November 3, involving 120 domestic and foreign companies [1] - The introduction of the commercial insurance innovative drug catalog is a significant highlight, marking its first establishment, with 141 submissions and 121 passing the preliminary review [1][2] - The NMI's focus is on "basic protection," which has led to high-value innovative drugs like CAR-T therapies not being included in the basic catalog, while the commercial insurance catalog aims to cover high-innovation drugs that exceed basic insurance limits [2] Group 1 - The NMI negotiations involved 127 drugs for the basic catalog and 24 for the commercial insurance catalog, with the new catalogs expected to be released in early December and implemented on January 1 [1] - The commercial insurance innovative drug catalog respects the market position of commercial insurance companies, differing from the NMI catalog adjustments [2] - Five CAR-T therapies are in the preliminary review for the commercial insurance catalog, indicating a growing acceptance of high-value therapies in the market [2][3] Group 2 - The support from commercial insurance for high-value innovative products like CAR-T therapies is seen as essential for risk-sharing among patients and promoting industry development [3] - There is a need for national involvement to enhance the role of commercial insurance in rare disease coverage, as profitability concerns may limit insurance companies' willingness to cover patients with pre-existing conditions [3] - The potential for innovative drugs included in both NMI and commercial insurance catalogs to experience rapid revenue growth is highlighted, benefiting patients and leading to increased flexibility for related companies [4]

Group 1 - MSCI announced the results of the November index review, with adjustments effective after the market close on November 24 [1] - The MSCI Global Small Cap Index will include 22 new stocks, such as Gilead Sciences (01672) and Meili Tianyuan Healthcare (02373) [1] - 17 stocks will be removed from the MSCI Global Small Cap Index, including China Gold International (02099) and China Nonferrous Mining (01258) [1] Group 2 - The MSCI Hong Kong Index will add 7 new stocks, including Chow Sang Sang (00116) and MGM China (02282) [2] - Stocks removed from the MSCI Hong Kong Index include Kintor Pharmaceutical (02171) and HKT Trust (00215) [2][3]